fenretinide
Trials 46 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06181760 Comparator | Nov 2023 → Feb 2024 | — | Island Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00429936 Comparator | Dec 2006 → May 2010 | diffuse secondary choroid atrophy, dry age related macular degeneration | Sirion Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00003099 Comparator | May 1996 → Jun 2000 | breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 54 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fenretinide | “Fenretinide is an anticancer agent that may work differently than standard chemotherapy medicines.” NCT02075177 ↗45“Active drug fenretinide (as LAU-7b capsules)” NCT03265288 ↗ |
| Known as | 4-HPR | “Induction of apoptosis is a unique feature of fenretinide (4-hydroxyphenylretinamide, 4-HPR),(2) the most widely studied retinoid in clinical trials of breast cancer...” NCT01479192 ↗10“A Multicenter Randomized Double-Blinded Trial for Chemoprevention of Ovarian Cancer: Modulation of Biomarkers and Spectral Properties Using Contrast Enhanced Ultrasound in...” NCT00098800 ↗ “The synthetic retinoid fenretinide (N-(4-hydroxyphenyl)retinamide, 4-HPR) has shown promising anticancer activity in preclinical studies, but its limited oral bioavailability...” PMID 21498721 ↗ Mar 2011 “A Randomized, Double Blind, Placebo-Controlled Phase II Clinical Trial of N(4-Hydroxy-phenyl)Retinamide (Fenretinide, 4HPR) in Oral Leukoplakia” NCT00004161 ↗ “Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder in Patients With Recurrent or Resistant Neuroblastoma” NCT00295919 ↗ “To evaluate the efficacy of fenretinide (4-HPR) in patients with recurrent ovarian cancer or primary peritoneal carcinoma.” NCT00026091 ↗ “Fenretinide (4-HPR) is a synthetic retinoid that induces cytotoxicity through dihydroceramide production.” PMID 37199745 ↗ May 2023 “4-HPR (Fenretinide) is given as a continuous intravenous infusion (CIV) for five consecutive days.” NCT00387504 ↗ “A Phase II Trial of Fenretinide (4-HPR) in Biochemically Recurrent, Hormone Naive Prostate Cancer” NCT00080899 ↗ “Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies” NCT00104923 ↗ “Fenretinide (4-HPR)” NCT00102635 ↗ |
| Known as | 4-hydroxyphenylretinamide | “Induction of apoptosis is a unique feature of fenretinide (4-hydroxyphenylretinamide, 4-HPR),(2) the most widely studied retinoid in clinical trials of breast cancer...” NCT01479192 ↗ |
| Known as | All-trans-4'-hydroxyretinanilide | ChEMBL registry synonym — accepted as the source's own label CHEMBL7301 ↗ |
| Known as | Dihydroceramide N-(4-Hydroxyphenyl retinamide) | “fenretinide (Dihydroceramide N-(4-Hydroxyphenyl retinamide) on severity” NCT00534898 ↗ |
| Known as | Fenretinida | ChEMBL registry synonym — accepted as the source's own label CHEMBL7301 ↗ |
| Known as | FMS | “The goal of this clinical trial is to determine the effect of a mucoadhesive system that releases the vitamin A derivative, fenretinide (FMS), on precancerous surface...” NCT07149220 ↗ |
| Known as | HPR | “Determine the maximum tolerated dose of fenretinide (HPR) in children with high risk solid tumors.” NCT00003191 ↗ |
| Known as | IND-40, 294 | “Phase II Trial Of Fenretinide (NSC-374551; IND-40, 294) In Patients With Relapsed Small Cell Lung Cancer” NCT00009971 ↗ |
| Known as | ISLA101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06528457 ↗ |
| Known as | LAU-7b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05999435 ↗ |
| Known as | LXS | “The purpose of this study is to determine the effectiveness of fenretinide (4-HPR/LXS) plus ketoconazole in the treatment of recurrent ovarian cancer or primary peritoneal carcinoma.” NCT01535157 ↗ |
| Known as | MCN-R-1967 | ChEMBL registry synonym — accepted as the source's own label CHEMBL7301 ↗ |
| Known as | N-(4-hydroxyphenyl)retinamide | “The synthetic retinoid fenretinide (N-(4-hydroxyphenyl)retinamide, 4-HPR) has shown promising anticancer activity in preclinical studies, but its limited oral bioavailability...” PMID 21498721 ↗ Mar 20111“A Randomized, Double Blind, Placebo-Controlled Phase II Clinical Trial of N(4-Hydroxy-phenyl)Retinamide (Fenretinide, 4HPR) in Oral Leukoplakia” NCT00004161 ↗ |
| Known as | NSC-374551 | “Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.” PMID 15514370 ↗ Nov 20044“Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder Plus Ketoconazole in Patients With Recurrent or Resistant Neuroblastoma” NCT02075177 ↗ “Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder in Patients With Recurrent or Resistant Neuroblastoma” NCT00295919 ↗ “Phase II Trial Of Fenretinide (NSC-374551; IND-40, 294) In Patients With Relapsed Small Cell Lung Cancer” NCT00009971 ↗ “A Phase I Study of Fenretinide (NSC #374551) in Children With High Risk Solid Tumors” NCT00003191 ↗ |
| Known as | NSC-760419 | ChEMBL registry synonym — accepted as the source's own label CHEMBL7301 ↗ |
| Known as | Rii retinamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL7301 ↗ |
| Modality | Small molecule | “Fenretinide, a synthetic form of retinoid” PMID 15744595 ↗ Mar 2005 |
| Route | Oral | “Patients also receive either oral fenretinide or oral placebo daily for 5 years, beginning within 2 weeks after completion of any radiotherapy, or within 2 weeks of...” NCT00002646 ↗ |